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patients in Lithuania: retrospective
national cohort study
Yanina Balabanova,1,2 Birute Radiulyte,3 Edita Davidaviciene,3 Richard Hooper,1
Olga Ignatyeva,2 Vladyslav Nikolayevskyy,1 Francis A Drobniewski1
ABSTRACT
Objective: To establish risk factors influencing
survival of patients with multidrug-resistant and
extensively drug-resistant tuberculosis (MDR/XDRTB).
Design: All MDR/XDRTB cases (n¼1809) reported
from 2002 to 2008 in Lithuania with a known outcome
were included in the survival analysis.
Results: Median survival for MDRTB and XDRTB
patients was 4.1 (95% CI 3.7 to 4.4) and 2.9 (95% CI
2.2 to 3.9) years. In a multivariable analysis adjusting
for other patient characteristics, the difference in
survival between MDRTB and XDRTB patients was not
significant (HR¼1.29 (0.91 to 1.81)). Older age
(HR¼4.80 (3.16 to 7.29)) for 60+ vs <30 years, rural
living (HR¼1.20 (1.02 to 1.40)), alcohol use (HR¼1.49
(1.13 to 1.96)) for alcoholic versus moderate use,
unemployment (HR¼1.79 (1.31 to 2.46)), lower
education levels (HR¼1.50 (1.08 to 2.07)) for primary
level versus tertiary level, cavitary disease (HR¼1.54
(1.29 to 1.83)) and being smear positive at the time of
MDR/XDRTB diagnosis (HR¼1.47 (1.19 to 1.82)) were
associated with poorer survival. HIV positivity
significantly affected survival (HR¼3.44 (1.92 to
6.19)) for HIV positive versus HIV negative; HR¼1.60
(1.28 to 2.01) for HIV not tested versus HIV negative).
There was no difference in survival of patients who
acquired MDR/XDRTB during treatment compared with
patients with primary MDR/XDRTB (HR¼1.01 (0.85 to
1.19)). Treatment with a second-line drug improved
survival (HR¼0.40 (0.34 to 0.47)). In a subgroup with
genotyped TB strains, a Beijing family of strains was
associated with poorer survival (HR¼1.71 (1.19 to
2.47)).
Conclusions: Social factors, rural living, HIV infection
and Beijing strain family impact on survival. Survival of
MDR/XDRTB patients is short. Rapid drug resistance
identification, early administration of appropriate
treatment and achieving high cure rates, expansion of
HIV testing and antiretroviral treatment are necessary
for optimal management of MDR/XDRTB.
INTRODUCTION
Multidrug-resistant (MDR) and extensively
drug-resistant (XDR) tuberculosis (TB)
threaten effective treatment and undermine
global efforts towards elimination of TB.1 2
The Baltic States have consistently had one of
the world’s highest rates of drug resistance
including MDRTB; MDRTB rates for 2009
were 62.1, 43.2 and 30.7/100 000 for
Lithuania, Latvia and Estonia, respectively.3
Our knowledge of drug resistance epidemi-
ology and its impact on patients’ population
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ARTICLE SUMMARY
Article focus
- The Baltic States have consistently had one of the
world’s highest rates of drug resistant tubercu-
losis (TB) including multidrug- and extensively
drug-resistant tuberculosis (MDR/XDRTB)
despite an extensive tuberculosis control
programmes.
- Patients with TB in Lithuania show a relatively
high mortality for unknown reasons.
- The study analyses factors influencing survival of
patients with MDR/XDRTB in Lithuania.
Key messages
- Patients with MDR/XDRTB show a poor survival
regardless of HIV status, but there was no
significant difference between MDRTB and
XDRTB.
- Patients infected with Beijing TB family strains
and co-infected with HIV with underlying social
problems have worse survival. However, only
few TB patients are tested for HIV.
- Addressing accompanying social and health
problems (eg, alcohol dependency), access to
care in rural settings and expansion of HIV
testing and antiretroviral treatment are necessary
to improve survival.
Strength and limitations of the study
- This is the first national study to analyse 7 years
of national surveillance data covering a large
cohort of MDR/XDRTB patients.
- The study demonstrates the value of long-term
survival cohorts, as well as pointing to the
absence of comparable UK data.
- Limitations: limited data on HIV status (due to
the low HIV testing coverage in the early years of
the TB programme) and limited genotyping data
for the XDRTB isolates.
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has come principally from studies from Estonia and
Latvia4e7 but relatively little is known about
Lithuania.8e11 However, Lithuania is one of the 18 high
priority TB countries in the European Region, has seen
an increase in rates of both primary and acquired
MDRTB (corresponding rates were 9% and 50% in 2010,
respectively) and appearance of XDRTB cases that in
2010 constituted 4.3% of all MDRTB cases (figure 1).12
Drug resistance is accompanied by high rates of default
(around 30%) and low treatment success rates (40% in
newly diagnosed and 19% in retreatment cases in 2009)
among MDRTB patients despite a well-established TB
control programme with relatively good indicators of
treatment success and low default rates (7%) among
patients with sensitive TB.12 Mortality rates among newly
diagnosed culture-confirmed cases is high (10.3%) and
is one of the highest in retreatment TB cases in the
WHO European Region (22.3%); the explanation for
the high mortality remains unknown.12
To answer this question, we analysed 7 years
(2002e2008) of Lithuanian national tuberculosis
surveillance data. Our aims were to describe the epide-
miological, clinical and socioeconomic features and
survival of a large national cohort of MDR/XDRTB cases
and to establish risk factors influencing their survival.
MATERIAL AND METHODS
Study population and data sources
The analysis was based on all MDRTB and XDRTB cases
including new and retreatment cases, confirmed by
conventional microbiological drug susceptibility testing
(DST) methods and registered for treatment from 2002
to 2008. The National TB Register (of the National TB
Surveillance system) was created in 2002 and used as the
source of data.
Standard case reporting includes demographic and
clinical information along with initial and follow-up DST.
The initial DST is performed on the first positive
mycobacterial culture for all cases; a follow-up test is
repeated if treatment failure or developed drug resis-
tance is suspected on a specimen collected at least
30 days after the initial specimen. DST is performed
using solid or automated liquid culture media system
(BACTEC MGIT 960; Becton Dickinson, Sparks,
Maryland, USA) according to standard procedures.13
A proportion of strains (all available MDR/XDRTB
isolates during 2004e2006 or approximately 20% of the
total with MDR/XDRTB) were genotyped (by IS6110
restriction fragment length polymorphism typing and
spoligotyping)14 15 by the Lithuanian Institute of
Biotechnology.
Case definitions
An MDRTB case was defined as a person infected with an
isolate resistant to at least isoniazid (INH) and rifam-
picin (RIF), excluding cases confirmed to have XDRTB.
MDRTB cases that had resistance to a fluoroquinolone
(FQ) and a second-line injectable (INJ, not strepto-
mycin) drug were defined as XDRTB cases. If an MDR or
XDRTB patient was registered for treatment and had
never received TB treatment in the past for longer than
4 weeks, he/she was considered to have primary drug
resistance. MDR/XDRTB patients who were retreatment
cases with a first episode of TB before 2002 were
assumed to have acquired TB.
Main outcome measures and statistical analysis
We used KaplaneMeier survival curves and multivariable
Cox regression to analyse time until death from any
cause during patient’s treatment or follow-up, from the
time of the first-recorded diagnosis of MDR or XDRTB
in the database. Patients who died or defaulted before
a diagnosis of TB was established were excluded from
the analysis. Cases from recent years who had not
completed their therapy or were still being followed up
were censored in April 2010 when the analysis was
conducted. The date of the last visit to a TB clinic was
recorded as the last day when a patient was documented
to be alive. Factors analysed in relation to survival were
MDR versus XDRTB and primary versus acquired TB, as
well as other characteristics assessed at the first TB
diagnosis: sex, age, rural/urban residence, contact with
TB, smoking, alcohol use, drug abuse, homelessness,
unemployment, education level, HIV status, co-
morbidity, TB type, smear positivity and cavitary disease.
Only patients with complete data were included in the
Figure 1 Trends in drug-
resistant cases of tuberculosis in
Lithuania, 2002e2010.
2 Balabanova Y, Radiulyte B, Davidaviciene E, et al. BMJ Open 2011;1:e000351. doi:10.1136/bmjopen-2011-000351
MDR/XDRTB survival, Lithuania
main analysis. (Note that this includes patients in three
categories of HIV status: positive, negative or not tested.
In a subsidiary analysis, we looked at the effect on
survival of TB strain family (Beijing/non-Beijing) in the
subsample of patients with genotyped strains, adjusting
for the variables in the main analysis.) The effect of
treatment with second-line drugs (SLDs; in the treat-
ment cycle where MDR/XDRTB was first diagnosed) was
modelled in a number of ways: we first looked for a trend
according to the number of SLDs used and compared
this with a model which compared any second-line
treatment with none. We also looked at effects of indi-
vidual drugs and of particular drug combinations,
adjusting for all variables in the main analysis. In addi-
tion to comparing the survival of XDR/MDRTB cases, we
assessed the effect of different resistance patterns at the
first TB diagnosis on survival, adjusting for the same
variables as in the analysis of MDR versus XDRTB. For
this analysis, patients were divided into eight resistance
patterns: (1) INH+RIF only, (2) INH+RIF+Ofloxacin
(‘Oflox’), (3) INH+RIF+INJ, (4) INH+RIF+Ethambutol/
Prothionamide (‘ETH/PT’), (5) INH+RIF+Oflox+INJ
(‘XDR’), (6) INH+RIF+Oflox+INJ+ETH/PT (‘XDR’),
(7) INH+RIF+Oflox+ETH/PT and (8) INH+RIF+INJ
+ETH/PT.
All analysis was performed using Stata V.11 (Stata
Corporation).
Ethics review
The project was reviewed by the Vilnius Regional
Committee for Biomedical Research Ethics, Vilnius
University and Queen Mary College Research Ethics
Committee and received a waver of informed consent as
anonymised data were used.
RESULTS
Study population
There were 1841 patients in the database with a diag-
nosis of MDR or XDRTB. Twenty-five were diagnosed
after the patient had died or defaulted and were
excluded. The last date of follow-up was unknown for
a further seven patients, and two patients had missing
data on smear positivity at the time of MDR/XDRTB
diagnosis. The analysis was done on the 1807 (98%)
patients with complete data.
Socio-demographic and clinical characteristics
The majority of MDR/XDRTB patients were young
Lithuanian-born males aged between 30 and 49 years
living in urban settings, unemployed, with primary
or secondary education and frequently consuming
alcohol (table 1). Drug abuse was relatively uncom-
mon. Most patients had pulmonary disease and were
smear positive at diagnosis. Over 60% of patients had
extensive lung damage with cavities identified on
radiographs. Relatively few patients (17.2%) were
tested for HIV infection as testing is not imposed by
national policies (although usually more MDR/XDRTB
patients are offered HIV testing than non-MDRTB
patients).
A proportion of MDRTB patients (13%) were resistant
to other SLDs in addition to resistance to isoniazid and
rifampicin but not meeting the definition of XDR.
Analysis of treatment regimes showed that 62.0% of
patients with MDRTB and 40.8% of patients with XDRTB
received fluoroquinolones and 34.9% and 35.2%,
respectively, received injectable SLDs. Ethionamide/
prothionamide was administered to over half of MDR/
XDRTB patients and cycloserine (CS) to 42.3% and
52.1% of MDRTB and XDRTB patients, respectively.
Negligible proportions of patients received terizidone
(TRD), amoxicillin/clavulanate (AMC) or thiacetazone
(THZ). P-aminosalicyclic acid (PAS) was administered to
1.3% of MDRTB and 28.2% of XDRTB patients (table 1).
The most commonly administered drug combinations
were FQ combined with group 4 drugs (ETH/PT, PAS,
terizidone (TRD)), or cycloserine and FQ, injectables
and group 4 drugs. For treatment of primary XDRTB in
addition to these regimens, a combination of injectables
and group 4 drugs was used in 15.5% of patients.
Survival analysis
The 1807 patients were followed for a total of
4089.3 person-years. Figure 2 shows KaplaneMeier plots
of the probability of survival depending on resistance
and HIV status. Median survival for MDR and XDRTB
patients was 4.0 (95% CI 3.7 to 4.4) and 2.9 (95% CI 2.2
to 4.3) years, respectively, and for HIV positive versus
HIV negative was 1.9 (95% CI 0.4 to 3.5) and 4.9 (95%
CI 4.3 to 6.8) years, respectively. Median survival of
patients with primary and acquired MDRTB was 4.2
(95% CI 3.7 to 5.1) and 3.7 (95% CI 3.4 to 4.3) years,
respectively; it was 2.7 (95% CI 1.8 to no upper limit)
and 2.9 (95% CI 1.4 to 4.9) years for primary and
acquired XDRTB patients, respectively.
Table 2 shows results of the multivariable analysis of
survival. Number of SLDs was associated with survival
after adjusting for other patient characteristics (HR per
drug 0.77, 95% CI 0.73 to 0.81, p<0.001). However,
there was no trend over and above the simple effect of
receiving any SLD treatment (mutually adjusted HR:
any treatment vs no treatment 0.42, 95% CI 0.29 to
0.59, p<0.001; per drug 0.98, 95% CI 0.88 to 1.10,
p¼0.78), so the results in table 2 adjust only for the
effect of any treatment. Older age, rural living, alcohol
use, unemployment, lower levels of education, positive
or unknown HIV status, cavity disease and being smear
positive at the time of MDR/XDRTB diagnosis were
all independently associated with poorer survival
(table 2). Once other patient characteristics were
adjusted for, there was no association of survival either
with acquired versus primary or with XDRTB versus
MDRTB. In the subsample of patients with genotyped
TB strains (n¼306), there was evidence that a Beijing
strain was associated with poorer survival after adjusting
for other factors (HR 1.70, 95% CI 1.18 to 2.45,
p<0.004).
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Table 1 Socio-demographic and clinical characteristic of MDR/XDRTB cases
Characteristics XDRTB (n[71), n (%) MDRTB (n[1736), n (%) Total (n[1807), n (%)
Male sex 56 (78.9) 1385 (79.8) 1441 (79.7)
Age category, y
<30 8 (11.3) 209 (12.0) 217 (12.0)
30e39 15 (21.1) 361 (20.8) 376 (20.8)
40e49 19 (26.8) 525 (30.2) 544 (30.1)
50e59 11 (15.5) 404 (23.3) 415 (23.0)
60+ 18 (25.4) 237 (13.7) 255 (14.1)
Country of birth
Lithuania 66 (93.0) 1657 (95.4) 1723 (95.4)
Russia 2 (2.8) 36 (2.1) 38 (2.1)
Belorussia 2 (2.8) 26 (1.5) 28 (1.5)
Ukraine 0 (0.0) 9 (0.5) 9 (0.5)
Other 1 (1.4) 8 (0.5) 9 (0.5)
Rural living 27 (38.0) 597 (34.4) 624 (34.5)
Contact with TB 8 (11.3) 81 (4.7) 89 (4.9)
Smoking 49 (69.0) 1363 (78.5) 1412 (78.1)
Alcohol*
Didn’t use 9 (12.7) 188 (10.8) 197 (10.9)
Sometimes 19 (26.8) 546 (31.5) 565 (31.3)
Often 33 (46.5) 852 (49.1) 885 (49.0)
Alcoholic 10 (14.1) 150 (8.6) 160 (8.9)
Drug abuse 1 (1.4) 35 (2.0) 36 (2.0)
Homelessness 4 (5.6) 134 (7.7) 138 (7.6)
Unemployment 62 (87.3) 1480 (85.3) 1542 (85.3)
Education
Less than primary 9 (12.7) 141 (8.1) 150 (8.3)
Primary/secondary 46 (64.8) 1267 (73.0) 1313 (72.7)
Tertiary 16 (22.5) 328 (18.9) 344 (19.0)
HIV
Negative 17 (23.9) 268 (15.4) 285 (15.8)
Positive 0 (0.0) 25 (1.4) 25 (1.4)
Not tested 54 (76.1) 1443 (83.1) 1497 (82.8)
Co-morbidity 2 (2.8) 42 (2.4) 44 (2.4)
TB type
Pulmonary 68 (95.8) 1657 (95.4) 1725 (95.5)
E/pulm 0 (0.0) 21 (1.2) 21 (1.2)
Pulmonary and e/pulm 3 (4.2) 58 (3.3) 61 (3.4)
Smear positivity 55 (77.5) 1343 (77.4) 1398 (77.4)
Cavity 47 (66.2) 1172 (67.5) 1219 (67.5)
Strain family
Non-Beijing 6 (8.5) 171 (9.9) 177 (9.8)
Beijing 10 (14.1) 119 (6.9) 129 (7.1)
Missing (not genotyped) 55 (77.5) 1446 (83.3) 1501 (83.1)
SLDs usedy
FQ 29 (40.8) 1077 (62.0) 1106 (61.2)
INJ 25 (35.2) 605 (34.9) 630 (34.9)
ETH/PT 42 (59.2) 1166 (67.2) 1208 (66.9)
CS 37 (52.1) 735 (42.3) 772 (42.7)
TRD 2 (2.8) 7 (0.4) 9 (0.5)
PAS 20 (28.2) 231 (13.3) 251 (13.9)
AMC 0 (0.0) 3 (0.2) 3 (0.2)
THZ 0 (0.0) 1 (0.1) 1 (0.1)
Combination of SLDs
No SLDs 20 (28.2) 425 (24.5) 445 (24.6)
INJ only (group 2) 0 (0.0) 4 (0.2) 4 (0.2)
FQ only (group 3) 0 (0.0) 18 (1.0) 18 (1.0)
ETH/PT or PAS or TRD
or CS only (group 4)
9 (12.7) 63 (3.6) 72 (4.0)
Groups 2 and 3 0 (0.0) 16 (0.9) 16 (0.9)
Continued
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We compared survival in eight different patient
subgroups defined by their patterns of resistance to SLDs
(see Methods). There was no evidence of differences
between these patient subgroups (p¼0.20).
We also looked at effects of individual drugs and
of individual drug combinations (table 3). Treatment
with fluoroquinolones, injectables, ethionamide or
prothionamide and cycloserine as well as with combi-
nations of these drug groups was associated with better
survival.
DISCUSSION
This is the first national study in Lithuania to examine
long-term survival in a large cohort of patients with
MDR/XDRTB. It complements smaller studies in other
Baltic States but with a longer follow-up period.5e7 16
Most MDR/XDRTB patients in Lithuania were young
men with accompanying social problems. These findings
describe a common distinct profile of TB patients in other
Eastern European regions5 7 16e21 drawing attention to
the high social marginalisation of this group.
Median survival of MDRTB and XDRTB patients was
around 4 and 3 years, respectively (similar to findings
from other settings).22 Although other studies demon-
strated a significant impact of XDR on survival,5 22e27 in
our study, median survival of XDRTB patients was not
significantly shorter than survival of MDRTB patients.
This finding might reflect the overwhelming effect of
MDRTB on survival and highlights the fact that many
patients although not XDRTB were ‘MDRTB plus’ with
resistance to many other SLDs. In these setting, the
difference between MDR and XDRTB might be less
prominent than elsewhere. Individuals with lower
survival rates were more likely to be older, alcohol
consuming, unemployed rural-based individuals who
had cavities in their lungs and remained sputum smear
positive. The association between smear positivity and
lethality is in line with poorer treatment outcome in
patients reported from Estonia.5
Extremely high rates of the Beijing TB strain family
among MDRTB cases support findings from other
studies in Eastern Europe including Russia,27e32
Table 1 Continued
Characteristics XDRTB (n[71), n (%) MDRTB (n[1736), n (%) Total (n[1807), n (%)
Groups 2 and 4 11 (15.5) 141 (8.1) 152 (8.4)
Groups 3 and 4 14 (19.7) 597 (34.4) 611 (33.8)
Groups 2, 3 and 4 14 (19.7) 443 (25.5) 457 (25.3)
Groups 3, 4 and other 0 (0.0) 2 (0.1) 2 (0.1)
Groups 2, 3, 4 and other 0 (0.0) 1 (0.1) 1 (0.1)
ETH/PT only 2 (2.8) 25 (1.4) 27 (1.5)
TRD or CS only 1 (1.4) 1 (0.1) 2 (0.1)
Resistance pattern
INH+RIF only 1513 (87.2) 1513 (83.7)
INH+RIF+Ofloxacin (‘Oflox’) 30 (1.7) 30 (1.7)
INH+RIF+INJ 124 (7.1) 124 (6.9)
INH+RIF+ETH/PT 32 (1.8) 32 (1.8)
INH+RIF+Oflox+INJ (‘XDR’) 43 (60.6) 43 (2.4)
INH+RIF+Oflox+INJ+ETH/PT
(‘XDR’)
28 (39.4) 28 (1.5)
INH+RIF+Oflox+ETH/PT 24 (1.4) 24 (1.3)
INH+RIF+INJ+ETH/PT 13 (0.7) 13 (0.7)
*Alcohol excess was determined by physicians and reported as stated in patients’ case histories according to nationally accepted breakdown
categorisation.
ySome patients received more than one drug, so numbers do not add to total n.
AMC, Amoxicillin/clavulanate; CS, Cycloserine; e/pulm, extrapulmonary tuberculosis; ETH/PT, Ethionamide/Prothionamide; FQ,
Fluoroquinolones; INH, isoniazid; INJ, injectables; MDR/XDRTB, multidrug- and extensively drug-resistant tuberculosis; PAS, P-aminosalicyclic
acid; RIF, rifampicin; SLD, second-line drugs; THZ, Thiacetazone; TRD, Terizidone.
Figure 2 Survival among (A)
multidrug-resistant (MDR) versus
extensively drug-resistant
tuberculosis (XDRTB) patients;
(B) MDR/XDRTB HIV-positive
versus MDR/XDRTB HIV-
negative cases.
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Estonia33 34 and Latvia.35 36 However, this study also
presented evidence that these strains are independently
associated with worse survival even after adjusting for the
effect of other characteristics.
HIV infection was associated with lower survival; only
half survived for up to 1.9 years from MDR/XDRTB
diagnosis. Unlike other Baltic States, this largely Catholic
country does not routinely offer HIV testing to TB
patients; initiation of testing would be of value particu-
larly for patients shown to have MDR/XDRTB where
highly active antiretroviral therapy would be of as much
importance for survival as anti-TB drugs.
There was no difference in survival of patients with
primary MDR or XDRTB compared with those who
developed drug resistance during treatment high-
lighting the overwhelming effect of drug resistance on
life expectancy.
Although the total number of MDR/XDRTB patients
receiving currently recommended treatment is rela-
tively small,37 38 it reflects the fact that as at the
beginning of the study treatment, guidelines were not
developed and SLDs not widely available. At the same
time, treatment regimens that include ethionamide/
prothionamide and cycloserine were commonly
administered for several months up to a year. However,
the prescription of any SLDs (even singly for ofloxacin,
injectables, ethionamide/prothionamide, cycloserine)
was associated with better survival. Taken together, the
results supported the importance of ofloxacin (and so
presumably FQ treatment in general) and injectable
agents in improving survival in line with the findings
of studies including a meta-analysis25 showing an im-
proved survival for XDRTB patients who received late-
generation FQs. Particularly, interesting was the
Table 2 Factors influencing survival of MDR/XDRTB patients*
Variable
Unadjusted Adjusted*
HR (95% CI) p Value HR (95% CI) p Value
XDR versus MDR 1.29 (0.92 to 1.81) 0.15 1.29 (0.91 to 1.81) 0.15
Acquired versus primary 1.28 (1.09 to 1.49) 0.002 1.01 (0.85 to 1.19) 0.92
Second-line drug 0.39 (0.33 to 0.45) <0.001 0.40 (0.34 to 0.47) <0.001
Male sex 1.44 (1.18 to 1.76) <0.001 1.05 (0.84 to 1.32) 0.65
Age
<30 1.00 <0.001 1.00 <0.001
30e39 3.06 (2.06 to 4.53) 2.71 (1.81 to 4.05)
40e49 3.81 (2.61 to 5.55) 3.14 (2.12 to 4.64)
50e59 3.73 (2.54 to 5.48) 3.11 (2.09 to 4.63)
60+ 5.36 (3.60 to 7.98) 4.80 (3.16 to 7.29)
Rural living 1.34 (1.16 to 1.55) <0.001 1.20 (1.02 to 1.40) 0.023
Contact with TB 0.58 (0.38 to 0.89) 0.012 0.93 (0.60 to 1.45) 0.75
Smoking 1.35 (1.11 to 1.63) 0.002 0.98 (0.78 to 1.24) 0.89
Alcohol
Didn’t use 1.01 (0.74 to 1.39) <0.001 1.11 (0.78 to 1.58) <0.001
Sometimes 1.00 1.00
Often 1.87 (1.56 to 2.24) 1.52 (1.26 to 1.84)
Alcoholic 1.94 (1.51 to 2.50) 1.49 (1.13 to 1.96)
Drug abuse 1.35 (0.86 to 2.10) 0.19 1.14 (0.69 to 1.88) 0.61
Homelessness 1.18 (0.92 to 1.50) 0.19 1.10 (0.84 to 1.44) 0.50
Unemployment 2.76 (2.04 to 3.75) <0.001 1.80 (1.31 to 2.46) <0.001
Education
Less than primary 1.99 (1.49 to 2.67) <0.001 1.50 (1.08 to 2.07) 0.020
Prim/secondary 1.51 (1.23 to 1.84) 1.30 (1.06 to 1.60)
Tertiary 1.00 1.00
HIV
Negative 1.00 <0.001 1.00 <0.001
Positive 3.93 (2.31 to 6.70) 3.44 (1.92 to 6.19)
Not tested 1.55 (1.25 to 1.93) 1.60 (1.28 to 2.01)
Co-morbidity 0.95 (0.59 to 1.51) 0.83 0.91 (0.56 to 1.46) 0.69
TB type
Pulmonary 1.00 0.65 1.00 0.37
E/pulm 0.63 (0.24 to 1.68) 1.39 (0.50 to 3.87)
Both 1.00 (0.67 to 1.49) 1.30 (0.86 to 1.96)
Cavity 1.61 (1.36 to 1.90) <0.001 1.54 (1.29 to 1.83) <0.001
Smear positivity 1.73 (1.42 to 2.13) <0.001 1.47 (1.19 to 1.82) 0.001
*Values are HRs and CIs from a Cox proportional hazards regression: unadjusted results are not adjusted for any confounders; adjusted results
are mutually adjusted for all variables in the table.
e/pulm, extrapulmonary tuberculosis; MDR, multidrug resistant ; XDRTB, extensively drug-resistant tuberculosis.
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importance of ethionamide/prothionamide therapy
used in combinations with ofloxacin and/or injectable
agents. A combination of ethionamide/prothionamide
with ofloxacin appeared to be at least as effective as
an FQ with an injectable. Although methods for DST
of ethionamide/prothionamide exist,39 40 the ability
to reliably demonstrate resistance remains difficult
and it is reasonable to argue that prothionamide
should always be added to an MDR/XDRTB treatment
regimen regardless of DST data. This provides
support for the current WHO combination drug class
approach.38
Even though survival time of MDR/XDRTB patients is
relatively short, it is long enough to establish a large pool
of individuals potentially infectious for others and facil-
itate further transmission of drug-resistant strains in the
community and in hospital settings where patients spend
up to 3 months. Early detection of MDR/XDRTB with
better infection control is therefore vital to interrupt
further transmission. Identification of MDRTB patients
should lead to their isolation with a regime consisting
of ethambutol, pyrazinamide, FQ, injectable and
ethionamide/prothionamide.
The strong association of drug resistance and worse
survival with social factors including alcohol abuse and
high rates of default among MDR/XDRTB cases are in
line with the findings of others41 and emphasise an
urgent need for non-medical interventions to improve
treatment outcomes. When this has been introduced
(eg, treatment of accompanying alcohol dependency), it
has improved treatment adherence and outcomes
significantly.42e44 The independent impact of rural
living on survival may indicate possible obstacles in
accessing TB treatment facilities in the country despite
a well-established system of TB care; the issue warrants
further investigation by local agencies.
The study has some limitations. HIV status was not
known for the majority of TB cases and therefore we
were unable to investigate further the association
between HIV, drug resistance and survival. Genotyping
was done for a relatively limited number of strains;
however, it provided sufficient data to identify statistically
significant association at least for a group of MDRTB
patients. Larger genetic studies are needed to answer the
question on influence of the strain type on survival
among XDRTB patients. Nevertheless, despite these
limitations, the study results can be generalised at least
for the Eastern European countries with similarly high
levels of TB, drug resistance and similar profile of
patients.
Table 3 Effect of different SLDs and their combination on survival of MDR/XDRTB patients*
Variable
Unadjusted Adjusted
HR (95% CI) p Value HR (95% CI) p Value
Effect of individual drugsy
FQ 0.55 (0.47 to 0.63) <0.001 0.55 (0.47 to 0.63) <0.001
INJ 0.76 (0.65 to 0.88) <0.001 0.82 (0.70 to 0.97) 0.016
ETH/PT 0.48 (0.41 to 0.55) <0.001 0.49 (0.43 to 0.57) <0.001
CS 0.60 (0.51 to 0.69) <0.001 0.66 (0.56 to 0.76) <0.001
TRD 0.89 (0.33 to 2.39) 0.82 0.79 (0.29 to 2.14) 0.65
PAS 0.74 (0.59 to 0.94) 0.012 0.86 (0.68 to 1.09) 0.21
AMC 0.84 (0.21 to 3.39) 0.81 1.06 (0.26 to 4.40) 0.94
THZ 8.49 (1.19 to 60.60) 0.033 5.89 (0.82 to 42.19) 0.079
Effect of combinations of drugsz
No SLDs 1.00 <0.001 1.00 <0.001
INJ only (group 2) 0.69 (0.17 to 2.76) 1.58 (0.39 to 6.48)
FQ only (group 3) 0.75 (0.37 to 1.52) 0.83 (0.41 to 1.68)
ETH/PT or PAS or TRD or
CS only (group 4)
0.45 (0.30 to 0.66) 0.42 (0.28 to 0.62)
Groups 2 and 3 0.78 (0.40 to 1.52) 0.82 (0.42 to 1.61)
Groups 2 and 4 0.40 (0.30 to 0.53) 0.43 (0.32 to 0.57)
Groups 3 and 4 0.36 (0.30 to 0.44) 0.36 (0.30 to 0.43)
Groups 2, 3 and 4 0.39 (0.32 to 0.47) 0.42 (0.35 to 0.52)
Groups 3, 4 and other 0.24 (0.03 to 1.74) 0.32 (0.04 to 2.38)
Groups 2, 3, 4 and other 1.03 (0.14 to 7.38) 1.29 (0.18 to 9.49)
ETH/PT only 0.31 (0.17 to 0.59) 0.37 (0.20 to 0.71)
TRD or CS only 1.73 (0.43 to 6.95) 0.98 (0.23 to 4.19)
*Values are HRs and CIs from a Cox proportional hazards regression: unadjusted results are not adjusted for any confounders; adjusted results
are adjusted for MDR versus XDRTB, primary versus acquired, sex, age, rural/urban residence, contact with TB, smoking, alcohol use, drug
abuse, homelessness, unemployment, education level, HIV status, co-morbidity, TB type, smear positivity and cavitary disease.
yEach drug analysed in a separate regression.
zResults of a single regression analysis with patients divided into 12 subgroups according to drug combination.
AMC, Amoxicillin/clavulanate; CS, Cycloserine; ETH/PT, Ethionamide/Prothionamide; FQ, Fluoroquinolones; INH, isoniazid; INJ, Injectables;
MDR/XDRTB, multidrug- and extensively drug-resistant tuberculosis; PAS, P-aminosalicyclic acid; RIF, rifampicin; SLD, second-line drugs;
THZ, Thiacetazone; TRD, Terizidone.
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In conclusion, rapid identification of drug resistance,
early administration of appropriate treatment, achieve-
ment of high cure rates, adequate infection control
measures, expansion of HIV testing and antiretroviral
treatment are necessary to improve patients’ survival and
prevent further spread of MDR and XDRTB in
Lithuania.
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